Research on multiple myeloma (MM) discovered that human osteoclast precursors expressed BDNF receptor TrkB and a Trk inhibitor, K252a, significantly decreased BDNF-stimulated osteoclast production, suggesting that BDNF utilized TrkB for its influence on osteoclasts. This evidence concerns the gene NTRK2 and AL amyloidosis.